{{Drugbox
| IUPAC_name = Methyl (2''S'')-2-{[1-(cyclohexylmethyl)-1''H''-indol-3-yl]formamido}-3,3-dimethylbutanoate
| image = MDMB-CHMICA.svg

<!--Clinical data-->
| tradename =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA = Schedule II
| legal_DE = Anlage II
| legal_UK = Class B
| legal_US = Schedule I
| legal_status = Illegal in Austria, China, Croatia, Denmark, Estonia, Finland, Greece, Hungary, Latvia, Lithuania, Luxembourg, Norway, Poland, Turkey, Sweden and Switzerland<ref name="EMCDDA"/>
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 1971007-95-0
| ATC_prefix =
| ATC_suffix =
| PubChem = 
| ChemSpiderID = 34450863
| smiles = COC(=O)[C@@H](NC(=O)c1cn(CC2CCCCC2)c3ccccc13)C(C)(C)C
| StdInChI = 1S/C23H32N2O3/c1-23(2,3)20(22(27)28-4)24-21(26)18-15-25(14-16-10-6-5-7-11-16)19-13-9-8-12-17(18)19/h8-9,12-13,15-16,20H,5-7,10-11,14H2,1-4H3,(H,24,26)/t20-/m1/s1
| StdInChIKey = SRJKCVHWIDFUBO-HXUWFJFHSA-N
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII =

<!--Chemical data-->
| C=23 | H=32 | N=2 | O=3
| molecular_weight = 
}}

'''MDMB-CHMICA''' (also incorrectly known as '''MMB-CHMINACA''') is an [[indole]]-based [[synthetic cannabinoid]] that is a potent [[agonist]] of the [[Cannabinoid receptor type 1|CB<sub>1</sub> receptor]] and has been sold online as a [[designer drug]].<ref name="EMCDDA"/><ref>{{cite web | url=https://www.caymanchem.com/Product.vm/catalog/16965 | title=MDMB-CHMICA | publisher=Cayman Chemical | accessdate=29 June 2015}}</ref><ref>{{cite web | url=http://forendex.southernforensic.org/index.php/detail/index/1305 | title=MDMB-CHMICA | publisher=Southern Association of Forensic Scientists | accessdate=29 June 2015}}</ref><ref>{{cite journal|first1=Samuel D.|last1=Banister|first2=Mitchell|last2=Longworth|first3=Richard|last3=Kevin|first4=Shivani|last4=Sachdev|title=Pharmacology of Valinate and ''tert''-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues|url=http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00137|journal=ACS Chemical Neuroscience|date=27 July 2016|doi=10.1021/acschemneuro.6b00137|pmid=    27421060|first5=Marina|last5=Santiago|first6=Jordyn|last6=Stuart|first7=James B. C.|last7=Mack|first8=Michelle|last8=Glass|first9=Iain S.|last9=McGregor|first10=Mark|last10=Connor|first11=Michael|last11=Kassiou|volume=7|pages=1241–54}}</ref> While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of [[MDMB-CHMINACA]]) has been identified on the designer drug market in 2015 as [[AMB-CHMINACA]].<ref>{{cite journal|first1=Vadim|last1=Shevyrin|first2=Vladimir|last2=Melkozerov|first3=Alexander|last3=Nevero|first4=Oleg|last4=Eltsov|title=Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl group|url=https://link.springer.com/article/10.1007/s00216-015-8612-7|journal=Analytical and Bioanalytical Chemistry|date=August 2015|pages=6301–6315|volume=407|issue=21|doi=10.1007/s00216-015-8612-7|pmid=25893797|first5=Yuri|last5=Shafran|first6=Yuri|last6=Morzherin|first7=Albert T.|last7=Lebedev}}</ref>

== Chemistry ==
Several commercial samples of MDMB-CHMICA were found to exclusively contain the (''S'')-enantiomer based on vibrational and electronic circular dichroism spectroscopy and X-ray crystallography.<ref>{{cite journal|first1=Lars|last1=Andernach|first2=Stefan|last2=Pusch|first3=Carina|last3=Weber|first4=Dieter|last4=Schollmeyer|title=Absolute configuration of the synthetic cannabinoid MDMB-CHMICA with its chemical characteristics in illegal products|url=https://link.springer.com/article/10.1007/s11419-016-0321-1|journal=Forensic Toxicology|date=1 June 2016|pages=344–352|volume=34|issue=2|doi=10.1007/s11419-016-0321-1|first5=Sascha|last5=Münster-Müller|first6=Michael|last6=Pütz|first7=Till|last7=Opatz}}</ref> An (S)-configuration for the ''tert''-leucinate group is unsurprising since MDMB-CHMICA is likely synthesized from the abundant and inexpensive "L" form of the appropriate ''tert''-leucinate reactant.

== Pharmacology ==

MDMB-CHMICA acts as a highly potent full [[agonist]] of the [[Cannabinoid receptor type 1|CB<sub>1</sub> receptor]] with an [[Intrinsic activity|efficacy]] of 94% and an [[EC50|EC<sub>50</sub>]] value of 0.14 nM, which is  approximately 8 times lower than the EC<sub>50</sub> of [[JWH-018]] (1.13 nM) and twofold lower than [[AB-CHMINACA]] (0.27 nM).<ref name="EMCDDA"/><ref>{{cite journal|first1=Nico|last1=Langer|first2=Rainer|last2=Lindigkeit|first3=Hans-Martin|last3=Schiebel|first4=Uli|last4=Papke|title=Identification and quantification of synthetic cannabinoids in “spice-like” herbal mixtures: update of the German situation for the spring of 2015|url=https://link.springer.com/article/10.1007/s11419-015-0292-7|journal=Forensic Toxicology|date=January 2016|pages=94–107|volume=34|issue=1|doi=10.1007/s11419-015-0292-7|first5=Ludger|last5=Ernst|first6=Till|last6=Beuerle}}</ref>

=== Metabolism ===
MDMB-CHMICA's main metabolic reactions comprise mono-hydroxylations and hydrolysis of the carboxylic ester function. In total, 31 metabolites could be identified in vivo.<ref>{{cite journal | url=https://www.gtfch.org/cms/images/stories/media/tb/tb2015/Franz_et_al_2015.pdf | title=Metabolism and urine analysis of the new synthetic cannabinoid MDMB-CHMICA |author1=Florian Franz |author2=Nadja Schwörer |author3=Verena Angerer |author4=Bjoern Moosmann |author5=Volker Auwärter | journal=Toxichem Krimtech | date=2015 | volume=82 | pages=192}}</ref><ref>{{cite journal|first1=Andrej|last1=Grigoryev|first2=Pierce|last2=Kavanagh|first3=Alexandr|last3=Pechnikov|title=Human urinary metabolite pattern of a new synthetic cannabimimetic, methyl 2-(1-(cyclohexylmethyl)-1''H''-indole-3-carboxamido)-3,3-dimethylbutanoate|url=https://link.springer.com/article/10.1007/s11419-016-0319-8|journal=Forensic Toxicology|date=July 2016|pages=316–328|volume=34|issue=2|doi=10.1007/s11419-016-0319-8}}</ref><ref>{{cite journal|first1=Florian|last1=Franz|first2=Verena|last2=Angerer|first3=Bjoern|last3=Moosmann|first4=Volker|last4=Auwärter|title=Phase I metabolism of the highly potent synthetic cannabinoid MDMB-CHMICA and detection in human urine samples|url=http://onlinelibrary.wiley.com/doi/10.1002/dta.2049/abstract|journal=Drug Testing and Analysis|date=August 2016|issn=1942-7611|pages=|doi=10.1002/dta.2049}}</ref>

== Side effects ==
71 serious adverse events, including 42 acute intoxications and 29 deaths (Germany (5), Hungary (3), Poland (1), Sweden (9), United Kingdom (10), Norway (1)) which occurred in 9 European countries between 2014 and 2016 have been associated with MDMB-CHMICA.<ref name="EMCDDA"/><ref>{{cite web | url=http://www.bbc.com/news/uk-england-derbyshire-32477643 | title=Derby legal high confusion prompts police warning | publisher=BBC | date=29 April 2015 | accessdate=29 June 2015}}</ref><ref>{{cite web | url=http://www.talkingdrugs.org/drug-alert-dangerous-synthetic-cannabinoid-mmb-chminaca-causing-hospitalizations-deaths-in-europe | title=Drug Alert: Dangerous Synthetic Cannabinoid MMB-CHMINACA Causing Hospitalizations, Deaths in Europe | publisher=TalkingDrugs | date=2 July 2015 | accessdate=2 July 2015}}</ref><ref>{{cite journal | url=http://jat.oxfordjournals.org/content/40/1/86 | title=Sudden Cardiac Death Following Use of the Synthetic Cannabinoid MDMB-CHMICA |author1=Andreas Austgulen Westin |author2=Joachim Frost |author3=Wenche Rødseth Brede |author4=Per Ole M. Gundersen |author5=Steinar Einvik |author6=Harald Aarset |author7=Lars Slørdal | journal=Journal of Analytical Toxicology | date=February 2016 | volume=40 | issue=1 | pages=86–87 | doi=10.1093/jat/bkv110 | pmid=26353925}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0379073816300469 | title=Fatal intoxication with synthetic cannabinoid MDMB-CHMICA | author=Piotr Adamowicz | journal=Forensic Science International | date=April 2016 | volume=261 | pages=e5–e10 | doi=10.1016/j.forsciint.2016.02.024 | pmid=26934903}}</ref>

Side effects such as unconsciousness or coma, hyperemesis, nausea, seizures, convulsions, tachycardia, bradycardia, mydriasis, syncope, spontaneous urinating and defecating, shortness of breath, somnolence, respiratory acidosis, metabolic acidosis, collapse, lower limbs paralysis, chest pain, aggression and severe disturbance of behaviour were reported.<ref name="EMCDDA"/><ref>{{cite journal|first1=Alice|last1=Seywright|first2=Hazel J.|last2=Torrance|first3=Fiona M.|last3=Wylie|first4=Denise A.|last4=McKeown|title=Analysis and clinical findings of cases positive for the novel synthetic cannabinoid receptor agonist MDMB-CHMICA|url=http://www.tandfonline.com/doi/abs/10.1080/15563650.2016.1186805|journal=Clinical Toxicology|date=13 September 2016|issn=1556-3650|pages=632–637|volume=54|issue=8|doi=10.1080/15563650.2016.1186805|first5=David J.|last5=Lowe|first6=Richard|last6=Stevenson|pmid=27213960}}</ref><ref>{{cite journal|first1=Simon L.|last1=Hill|first2=Javad|last2=Najafi|first3=Michael|last3=Dunn|first4=Paul|last4=Acheampong|title=Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1190980|journal=Clinical Toxicology|date=13 September 2016|issn=1556-3650|pages=638–643|volume=54|issue=8|doi=10.1080/15563650.2016.1190980|pmid=27251903|first5=Ashraf|last5=Kamour|first6=Johann|last6=Grundlingh|first7=Peter G.|last7=Blain|first8=Simon H. L.|last8=Thomas}}</ref><ref>{{cite journal|first1=Robert J.|last1=Tait|first2=David|last2=Caldicott|first3=David|last3=Mountain|first4=Simon L.|last4=Hill|title=A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment|url=http://www.tandfonline.com/doi/abs/10.3109/15563650.2015.1110590|journal=Clinical Toxicology|date=2 January 2016|pages=1–13|volume=54|issue=1|doi=10.3109/15563650.2015.1110590|pmid=26567470|first5=Simon|last5=Lenton}}</ref><ref>{{cite journal|first1=Chitra|last1=Meyyappan|first2=Loretta|last2=Ford|first3=Allister|last3=Vale|title=Poisoning due to MDMB-CHMICA, a synthetic cannabinoid receptor agonist|url=http://www.tandfonline.com/doi/full/10.1080/15563650.2016.1227832|journal=Clinical Toxicology|date=2016|issn=1556-3650|pages=1–2|pmid=27635694|doi=10.1080/15563650.2016.1227832}}</ref><ref>{{cite journal|first1=Matilda|last1=Bäckberg|first2=Luiza|last2=Tworek|first3=Olof|last3=Beck|first4=Anders|last4=Helander|title=Analytically Confirmed Intoxications Involving MDMB-CHMICA from the STRIDA Project|url=https://link.springer.com/article/10.1007/s13181-016-0584-2|journal=Journal of Medical Toxicology|date=2016|issn=1937-6995|doi=10.1007/s13181-016-0584-2|pmid=27638057}}</ref>

== Legal status ==

In the United States, MDMB-CHMICA is a [[Controlled_Substances_Act#Schedule_I_controlled_substances|Schedule I controlled substance]].<ref>{{cite web | url = https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1221.htm | title = Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I | publisher = [[Drug Enforcement Administration]]}}</ref>

MDMB-CHMICA is illegal in Austria, Canada, China,<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref> Croatia, Denmark, Estonia, Finland, Germany, Greece, Hungary, Latvia, Lithuania, Louisiana,<ref>{{cite web | url=http://dhh.louisiana.gov/index.cfm/newsroom/detail/3161 | title=Gov. Jindal and State Officials Ban New Synthetic Marijuana Compound | accessdate=29 June 2015}}</ref> Luxembourg, Norway, Turkey, the UK,<ref name="Drugswheel">{{cite url|url=http://www.thedrugswheel.com/downloads/TheDrugsWheel_2_0_3.pdf|title=Drugs Wheel 2.0.3}}</ref>{{Dubious|Source stated Poland and that's false statement|date=June 2017}} Sweden and Switzerland.<ref name="EMCDDA"/>

In August 2016 the [[European Commission]] proposed a ban on MDMB-CHMICA across the [[European Union]].
<ref>{{cite web | url=http://www.emcdda.europa.eu/news/2016/NPS-Commission | title=New psychoactive substances: Commission proposes new ban and strengthens the EU's Early Warning System and risk assessment | publisher=[[European Monitoring Centre for Drugs and Drug Addiction]] (EMCDDA) | date=31 August 2016 | location=Lisbon}}</ref>
In 27 February 2017 the commission adopted an implementing act in banning MDMB-CHMICA, and [[Member state of the European Union|Member States]] shall take the necessary measures to subject it to control measures and criminal penalties no later than by 4 March 2018.
<ref>{{cite web | url=http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017D0369&from=EN | title=COUNCIL IMPLEMENTING DECISION (EU) 2017/369 | publisher=[[European Commission]] | date=27 February 2017 | location=Brussels}}</ref>

=== Seizures ===

Over 3600 MDMB-CHMICA seizures between 2014 and 2016 in 19 member states of the European Union have been reported to the [[European Monitoring Centre for Drugs and Drug Addiction]] (EMCDDA),<ref name="EMCDDA">{{cite web | url=http://www.emcdda.europa.eu/system/files/publications/2873/2016.4528_WEB.pdf | title=EMCDDA–Europol Joint Report on MDMB-CHMICA | publisher=European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) | date=July 2016 | doi=10.2810/08132 | isbn=978-92-9168-925-5}}</ref> including a 40&nbsp;kg seizure [sic] in Luxembourg in December 2014.<ref>{{cite web | url=https://www.unodc.org/documents/scientific/Global_SMART_Update_13_web.pdf | title=Global SMART update | publisher=United Nations Office on Drugs and Crime | date=13 March 2015 | accessdate=29 June 2015}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[AB-CHMINACA]]
* [[ADB-CHMINACA]]
* [[AMB-CHMINACA]]
* [[MDMB-CHMINACA]]
* [[MDMB-FUBINACA]]
* [[PX-3]]
{{Div col end}}

==References==
{{Reflist}}

{{Cannabinoids}}
{{Cannabinoidergics}}

[[Category:Indoles]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indolecarboxamides]]